Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21;11(14):4237.
doi: 10.3390/jcm11144237.

Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Diona Gjermeni  1 , Hannah Vetter  1 , Sofia Szabó  1 , Viktoria Anfang  1 , Stefan Leggewie  1 , David Hesselbarth  1 , Daniel Duerschmied  2   3 , Dietmar Trenk  1 , Christoph B Olivier  1
Affiliations

Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Diona Gjermeni et al. J Clin Med. .

Abstract

Background: High on-clopidogrel platelet reactivity (HPR) following percutaneous coronary intervention (PCI) is associated with increased ischemic risk. It is unclear whether conventional definitions of HPR apply to patients with concomitant oral anticoagulation (OAC). This study aimed to compare the performance of multiple platelet aggregometry (MEA) and thrombelastography (TEG) to detect HPR in patients with atrial fibrillation (AF) and indication for an OAC. Methods: In this observational single-center cohort study, MEA and TEG were performed in patients with AF with an indication for OAC on day 1 to 3 after PCI. The primary outcome was HPR as assessed by MEA (ADP area under the curve ≥ 46 units [U]) or TEG (MAADP ≥ 47 mm), respectively. The secondary exploratory outcomes were a composite of all-cause death, myocardial infarction (MI) or stroke and bleeding, as defined by the International Society on Thrombosis and Hemostasis, at 6 months. Results: Platelet function of 39 patients was analyzed. The median age was 78 (interquartile range [IQR] was 72−82) years. 25 (64%) patients were male, and 19 (49%) presented with acute coronary syndrome. All patients received acetylsalicylic acid and clopidogrel prior to PCI. Median (IQR) ADP-induced aggregation, MAADP, TRAP-induced aggregation, and MAthrombin were 9 (6−15) U, 50 (43−60) mm, 54 (35−77) U and 65 (60−67) mm, respectively. The rate of HPR was significantly higher if assessed by TEG compared with MEA (25 [64%] vs. 1 [3%]; p < 0.001). Within 6 months, four (10%) deaths, one (3%) MI and nine (23%) bleeding events occurred. Conclusion: In patients with AF undergoing PCI, the rates of HPR detected by TEG were significantly higher compared with MEA. Conventional cut-off values for HPR as proposed by consensus documents may need to be re-evaluated for this population at high ischemic and bleeding risk. Further studies are needed to assess the association with outcomes.

Keywords: atrial fibrillation; multiple electrode aggregometry; percutaneous coronary intervention; platelet reactivity; thrombelastography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Platelet reactivity of patients with atrial fibrillation undergoing percutaneous intervention. (A) ADP- and (C) TRAP-induced aggregation as assessed by MEA and MAADP (B) and MAThrombin (D) as assessed by TEG. Median and interquartile range are represented by black lines. Red lines indicate conventional cut-off values (ADP AUC ≥ 46 U and MAADP ≥ 47 mm) or reference values suggested by the manufacturer (TRAP AUC 94-156 U, MAThrombin 53–68 mm), respectively.
Figure 2
Figure 2
Platelet reactivity according to oral anticoagulation. Aggregation values for ADP-induced aggregation as assessed by MEA (A) and MAADP as assessed by TEG (B) with and without OAC therapy. Red line represents HPR cut-off and black line median with interquartile range.
Figure 3
Figure 3
Correlation of multiple electrode aggregometry with thrombelastography. ADP AUC with MAADP (A) and TRAP AUC with MAThrombin (B).
See this image and copyright information in PMC

References

    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.A., Dilaveris P.E., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612. - DOI - PubMed
    1. Olivier C.B., Turakhia M.P., Mahaffey K.W. Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. Expert Opin. Drug Saf. 2018;17:251–258. doi: 10.1080/14740338.2018.1424827. - DOI - PubMed
    1. Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R., Goodman S.G., Windecker S., Darius H., Li J., et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N. Engl. J. Med. 2019;380:1509–1524. doi: 10.1056/NEJMoa1817083. - DOI - PubMed
    1. Vranckx P., Valgimigli M., Eckardt L., Tijssen J., Lewalter T., Gargiulo G., Batushkin V., Campo G., Lysak Z., Vakaliuk I., et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial. Lancet. 2019;394:1335–1343. doi: 10.1016/S0140-6736(19)31872-0. - DOI - PubMed
    1. Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y., Ellis S.G., Kimura T., Maeng M., Merkely B., Zeymer U., Gropper S., et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N. Engl. J. Med. 2017;377:1513–1524. doi: 10.1056/NEJMoa1708454. - DOI - PubMed

LinkOut - more resources